1. Home
  2. EIKN vs EOLS Comparison

EIKN vs EOLS Comparison

Compare EIKN & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eikon Therapeutics Inc. Common Stock

EIKN

Eikon Therapeutics Inc. Common Stock

HOLD

Current Price

$7.26

Market Cap

631.0M

Sector

Health Care

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

SELL

Current Price

$7.77

Market Cap

529.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EIKN
EOLS
Founded
2019
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
631.0M
529.1M
IPO Year
2026
2018

Fundamental Metrics

Financial Performance
Metric
EIKN
EOLS
Price
$7.26
$7.77
Analyst Decision
Buy
Buy
Analyst Count
6
6
Target Price
★ $24.60
$15.00
AVG Volume (30 Days)
★ 626.1K
619.3K
Earning Date
11-06-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1.23
EPS
N/A
★ N/A
Revenue
N/A
★ $297,176,000.00
Revenue This Year
N/A
$12.44
Revenue Next Year
N/A
$17.37
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 11.61
52 Week Low
$7.02
$3.86
52 Week High
$16.50
$9.31

Technical Indicators

Market Signals
Indicator
EIKN
EOLS
Relative Strength Index (RSI) 32.44 47.94
Support Level $7.02 $7.59
Resistance Level $10.20 $8.47
Average True Range (ATR) 0.54 0.31
MACD 0.01 -0.01
Stochastic Oscillator 12.21 48.96

Price Performance

Historical Comparison
EIKN
EOLS

About EIKN Eikon Therapeutics Inc. Common Stock

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: